Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Despite the standard of care, patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) progress to dialysis, are hospitalized for heart failure and die prematurely. Overactivation of the mineralocorticoid receptor (MR) causes inflammation and fibrosis that damages the kidney and heart. Finerenone, a nonsteroidal, selective MR antagonist, confers kidney and heart protection in both animal models and Phase II clinical studies; the effects on serum potassium and kidney function are minimal. Comprising the largest CKD outcomes program to date, FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) and FIGARO-DKD (FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease) are Phase III trials investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes from early to advanced CKD in T2D. By including echocardiograms and biomarkers, they extend our understanding of pathophysiology; by including quality of life measurements, they provide patient-centered outcomes; and by including understudied yet high-risk cardiorenal subpopulations, they have the potential to widen the scope of therapy in T2D with CKD. Trial registration number: FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![FIGURE 5. Comparison of baseline median UACR (mg/g) and mean eGFR (mL/min/1.73 m2) of patients enrolled in recent trials investigating cardiovascular and/or renal outcomes in patients with CKD in T2D (circle sizes are proportional to the population sizes of the trials.) [12, 14, 43–49].](https://figures.cochat.ai/paper-figures/3885cb17fe794e879beb8fb60f6eadd0/investigating-new-treatment-opportunities-for-patients-with-chronic-kidney-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even with current therapies available [6–10], patients with T2DM and chronic kidney disease (CKD) still experience a significant cardiovascular and renal morbidity and mortality.”
The cited source says what the claim attributes to it.
In the citing paper
“They investigated the efficacy and safety of finerenone, on top of maximum tolerated renin–angiotensin system inhibition, on kidney and cardiovascular outcomes in patients with mild-to-severe CKD in type 2 diabetes (Supplementary material online, Figure S1).3”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with chronic kidney disease (CKD) and type 2 diabetes have high residual cardiorenal morbidity and mortality, despite current therapies,1–5”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Patient characteristics, medications, and demographics at baseline were balanced between patients randomized to finerenone and placebo (Table 2 and Supplementary material online, Table S1; published previously3).”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · cited 1×
“The available steroidal MRAs, spironolactone and eplerenone, are both effective in reducing mortality and hospitalization in the treatment of heart failure [22, 23]; however, their role in reducing the rate of progression of kidney disease to ESKD is unknown.”
BackgroundSelf-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“However, despite the use of ACEis or ARBs and the concomitant use of SGLT2is, there remains an unmet need to reduce both the residual risk of progression to ESKD and CV morbidity and mortality [11, 14].”
BackgroundSelf-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · cited 1×
“The available steroidal MRAs, spironolactone and eplerenone, are both effective in reducing mortality and hospitalization in the treatment of heart failure [22, 23]; however, their role in reducing the rate of progression of kidney disease to ESKD is unknown.”
BackgroundSelf-citationDiabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898 · cited 1×
“However, despite the use of ACEis or ARBs and the concomitant use of SGLT2is, there remains an unmet need to reduce both the residual risk of progression to ESKD and CV morbidity and mortality [11, 14].”
BackgroundAndrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213 · cited 2×
“Albuminuria is an independent risk marker for CV and allcause mortality, even at levels within the upper normal range [8, 9].”
BackgroundPlasma aldosterone regulation in anephric man
Walker, W. G., & Cooke, C. R. (1973) · Kidney International · doi:10.1038/ki.1973.1 · Cited by 1,841
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Research works printed but not linked: 2
- International Diabetes Federation, 2019, IDF Diabetes Atlas
- Pavkov, 2018, Diabetes in America
Cited by
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citationAgarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
“They investigated the efficacy and safety of finerenone, on top of maximum tolerated renin–angiotensin system inhibition, on kidney and cardiovascular outcomes in patients with mild-to-severe CKD in type 2 diabetes (Supplementary material online, Figure S1).(3) In FIDELIO-DKD, finerenone significantly reduced the risk…”
Self-citationSignaling Pathways Involved in Diabetic Renal Fibrosis
Zhang, Y., Jin, D., Kang, X., Zhou, R., Sun, Y., Lian, F., & Tong, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696542 · Cited by 210
The Bidirectional Link Between Diabetes and Kidney Disease: Mechanisms and Management
Kumar, M., Dev, S., Khalid, M., Siddenthi, S. M., Noman, M., John, C. L., Akubuiro, C., Haider, A., Rani, R., Kashif, M., et al. (2023) · Cureus · doi:10.7759/cureus.45615 · Cited by 159
“Carbohydrates have a notable impact on blood glucose levels, and individuals with diabetes should prioritize consuming complex carbohydrates with a low glycemic index [19].”
BackgroundZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
Kolkhof, P., Joseph, A., & Kintscher, U. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105859 · Cited by 94
Self-citationBakris, G. L., Ruilope, L. M., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Fried, L. P., Roy‐Chaudhury, P., Sarafidis, P. A., Ahlers, C., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.040 · Cited by 102
Self-citationGembillo, G., Ingrasciotta, Y., Crisafulli, S., Luxi, N., Siligato, R., Santoro, D., & Trifirò, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094824 · Cited by 113
Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
Georgianos, P. I., & Agarwal, R. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.027 · Cited by 87
Self-citationFilippatos, G. S., Anker, S. D., Pitt, B., Rossing, P. R., Joseph, A., Kolkhof, P., Lambelet, M., Lawatscheck, R., Bakris, G. L., Ruilope, L. M., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.07.013 · Cited by 92
Self-citationFrampton, J. E. (2021) · Drugs · doi:10.1007/s40265-021-01599-7 · Cited by 82
“Implicated in chronic pathophysiological disease states, such as type 2 diabetes (T2D) and chronic kidney disease (CKD), overactivation of the mineralocorticoid receptor (MR) by aldosterone and cortisol results in high levels of inflammation and fibrosis leading to cardiorenal end-organ damage [1, 2].”
BackgroundCardiorenal benefits of finerenone: protecting kidney and heart
González‐Juanatey, J. R., Górriz, J. L., Ortíz, A., Valle, A., Soler, M. J., & Fácila, L. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2171110 · Cited by 95
Georgianos, P. I., & Agarwal, R. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac124 · Cited by 69
Self-citationHyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
Valdivielso, J. M., Balafa, O. C., Ekart, R., Ferro, C. J., Mallamaci, F., Mark, P. B., Rossignol, P., Sarafidis, P. A., Vecchio, L. D., & Ortíz, A. (2021) · Drugs · doi:10.1007/s40265-021-01555-5 · Cited by 62
Lullo, L. D., Lavalle, C., Scatena, A., Mariani, M. V., Ronco, C., & Bellasi, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123992 · Cited by 55
“It exhibits a balanced tissue distribution between the heart and kidney and, most importantly, is associated with a lower risk of hyperkalemia, as evidenced by the results of phase I and phase II clinical trial programs (Figure 1) [3].”
BackgroundAlkhatib, L., Díaz, L. A. V., Varma, S., Chowdhary, A., Bapat, P., Pan, H., Kukreja, G., Palabindela, P., Selvam, S. A., & Kalra, K. (2023) · Cureus · doi:10.7759/cureus.34572 · Cited by 56
“In comparison to spironolactone, finerenone causes less hyperkalemia [67].”
BackgroundLerma, E. V., & Wilson, D. J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094770 · Cited by 46
“inflammation and fibrosis in the kidneys, blood vessels, and heart, leading to the progression of cardiorenal disease [8,11].”
BackgroundSarafidis, P., Papadopoulos, C. E., Kamperidis, V., Giannakoulas, G., & Doumas, M. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17005 · Cited by 39
Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy
Ma, L., Liu, D., Yu, Y., Li, Z., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1587806 · Cited by 51
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Hojs, N. V., Bevc, S., Ekart, R., Piko, N., Petreski, T., & Hojs, R. (2021) · Pharmaceuticals · doi:10.3390/ph14060561 · Cited by 30
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice
Desai, N. R., Navaneethan, S. D., Nicholas, S. B., Pantalone, K. M., Wanner, C., Hamacher, S., Gay, A., & Wheeler, D. C. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108411 · Cited by 34
“11,28 Finerenone inhibits MR overactivation and forms a complex with the MR that affects cofactor recruitment and binding to the MR. 26,29,30 Finerenone induces a distinct cardiac gene expression profile compared with a steroidal MRA, assessed ex vivo in a model of cardiac hypertrophy.”
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
Shah, M., Awad, A. S., & Abdel‐Rahman, E. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196285 · Cited by 30
“Importantly, unlike spironolactone and eplerenone, finerenone has a short half-life that may explain its minimal effects on serum potassium levels [13].”
Novel Therapeutic Approaches in the Management of Chronic Kidney Disease
Dąbek, B., Dybiec, J., Frąk, W., Fularski, P., Lisińska, W., Radzioch, E., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11102746 · Cited by 42
“A comparison of the inclusion criteria is shown in Table 2 below [58,59,66].”
BackgroundMethodAlbakr, R. B., Sridhar, V. S., & Cherney, D. Z. I. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.04.015 · Cited by 25
Qiu, C., Liu, S., Li, X., Li, W., Hu, G., & Liu, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-40429-6 · Cited by 24
Schaefer, F. S., Montini, G., Kang, H. G., Walle, J. V., Zaritsky, J. J., Schreuder, M. F., Litwin, M., Scalise, A. V., Scott, H., Potts, J., et al. (2024) · Trials · doi:10.1186/s13063-024-08021-z · Cited by 30
Rossing, P. R. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.005 · Cited by 25
“The similarities in intervention, design, and endpoints will make it possible to analyze the combined cohort covering the spectrum of CKD in T2D, from early to late stages (Table 2).(63,64,66)”
BackgroundSelf-citationSteroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
Gregg, L. P., & Navaneethan, S. D. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac284 · Cited by 21
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02053-6 · Cited by 20
Wish, J. B., & Pérgola, P. E. (2022) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2022.09.002 · Cited by 24
“Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD, NCT02540993) is a phase 3 study investigating the efficacy of finerenone on kidney outcomes in patients with CKD and T2DM, who were treated with an ACEi/ARB at optimized doses.(64,84,88,94) Treatment with finerenone…”
Methodvan den Berg, P., Ruppert, M., Mešić, E., Snelder, N., Seelmann, A., Heinig, R., Joseph, A., Garmann, D., Lippert, J., & Eißing, T. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01082-2 · Cited by 23
“The mode of action of finerenone is primarily through organ protection by counteracting inflammatory and fibrotic processes, including in the kidneys and heart, mediated by overactivation of the mineralocorticoid receptor and aldosterone upregulation [1, 7, 8].”
BackgroundSelf-citationAdhikary, K., Sarkar, R., Maity, S., Banerjee, I., Chatterjee, P., Bhattacharya, K., Ahuja, D., Sinha, N. K., & Maiti, R. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0043 · Cited by 21
Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency
Lin, Z., Li, Y., Zhao, Y., Liu, D., Deng, S.-Z., Gu, J., Li, Y., Zhao, X., Wu, P., Xiao, Y., et al. (2026) · Science · doi:10.1126/science.adz4075 · Cited by 25
Chen, X., Li, X., Zhang, K., Lian, K., Zhang, W., Song, Y., Kan, C., Zhang, J., Han, F., Sun, X., et al. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02413-2 · Cited by 19
“Selective MRAs, such as finer-enone, offer a promising approach to achieve this goal [28].”
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 22
Fels, B., Beyer, A., Cazaña‐Perez, V., Giráldez, T., Navarro‐González, J. F., de la Rosa, D. Á., Schaefer, F. S., Bayazıt, A. K., Obrycki, Ł., Ranchin, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810659 · Cited by 16
“Recent and ongoing clinical trials show cardioprotective and nephroprotective effects of treatment with non-steroidal selective MR antagonists in CKD patients and further underscore the important role of the MR in CKD-related cardiovascular damage [17].”
BackgroundA new perspective on proteinuria and drug therapy for diabetic kidney disease
Zhang, R., Wang, Q., Li, Y., Li, Q., Zhou, X., Chen, X., & Dong, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349022 · Cited by 25
Solis‐Herrera, C., & Triplitt, C. L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15327 · Cited by 18
Khan, M. S., & Lea, J. P. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03652-5 · Cited by 19
“The overactivation of the MR may lead to inflammation and fibrosis in the heart and kidney [74, 75].”
BackgroundD’Marco, L., Puchades, M. J., Gandía, L., Forquet, C., Giménez-Civera, E., Panizo, N., Reque, J., Juan-García, I., Bermúdez, V., Facultad de Ciencias de la Salud, U. S. B., et al. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.84 · Cited by 15
“Indeed, it has been reported that finerenone reduced albuminuria after 4 months of treatment, with minimal effects on blood pressure and glycaemia.(22,23)”
BackgroundIncreased glucocorticoid metabolism in diabetic kidney disease
Ackermann, D., Vogt, B., Bochud, M., Burnier, M., Martin, P., Paccaud, F. M., Ehret, G., Guessous, I., Ponte, B., Pruijm, M. T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269920 · Cited by 15
Arici, M., ALTUN, B., Araz, M., Atmaca, A. A., Demir, T., Ecder, T., Güz, G., Yavuz, D. G., Yildiz, A., & Yilmaz, T. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1384454 · Cited by 19
Therapeutic approaches and novel antifibrotic agents in renal fibrosis: A comprehensive review
Lahane, G. P., Dhar, A., & Bhat, A. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23795 · Cited by 14
Redón, J. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvac024 · Cited by 11
Ortíz, A., Arroyo, R. A., Escribano, P. P. C., Fernández‐Fernández, B., Debén, F. M., Mediavilla, J. D., Doña, A. M., Soler, M. J., & Górriz, J. L. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2213888 · Cited by 12
Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease
Verma, A., & Patel, A. B. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.002 · Cited by 11
Salh, H. J. H., Aziz, T. A., Mahwi, T., Hussen, N. H., & Aziz, D. F. (2025) · Hospital Pharmacy · doi:10.1177/00185787251337592 · Cited by 9
“43 Additionally, we reported no significant association between liver function (AST and ALT) and polypharmacy.”
Vergara, A., Llorens-Cebrià, C., Martos, N., Martínez-Díaz, I., Stein, F., Domínguez, P., den Bosch, M. M. V., Rettel, M., Benito, B., Bermejo, S., et al. (2023) · Clinical Science · doi:10.1042/cs20220447 · Cited by 9
Aldosterone in Chronic Kidney Disease
Polenus, P., Đuran, A., & Karanović, S. (2025) · Biomedicines · doi:10.3390/biomedicines13092081 · Cited by 11
“As a result, patients often face a significant residual risk of CKD progression and cardiovascular events [57].”
Finerenone: Evidence for Benefit in Early Stages of Cardiovascular-Kidney-Metabolic Syndrome
Márquez, D. F., Ortíz, A., González‐Moreno, D., Ruilope, L. M., & Ruiz‐Hurtado, G. (2025) · Cardiorenal Medicine · doi:10.1159/000548494 · Cited by 8
“Nonsteroidal MRA has heralded a new era in the management of patients with CKD and CVD. Finer-enone differs from classical steroidal MRAs in several key molecular aspects: it exhibits greater selectivity for the mineralocorticoid receptors and has comparable efficacy to spironolactone [16].”
Self-citationRastogi, A., & Weir, M. R. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108515 · Cited by 8
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v1 · Cited by 7
Swapna, B., Fathima, K., Muwayyad, H., Khanam, M., Salma, S., Harsha, S., & Gayas, N. (2024) · Cellular Molecular and Biomedical Reports · doi:10.55705/cmbr.2023.420751.1184 · Cited by 8
Palomo‐Piñón, S., Aguilar-Alonso, J. A., Chavez-Iñiguez, J. S., Hernández-Arellanes, F. E., Mariano-Murga, J. A., Flores-Rodríguez, J. C., Pérez-López, M. J., Pérez, F. P., Treviño–Becerra, A., Guillén-Graf, A. E., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1376115 · Cited by 9
“The main ones include sorbitol formation, oxidative stress escalation, protein kinase C activation, and hexosamine pathway activation (13, 14).”
BackgroundFinerenone’s Promise in Heart Failure and Kidney Disease
Shokri, K., Mohammadi, A., Karimian, A., Adeel, M. Y., Mozaffari, M. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000958 · Cited by 5
Eight weeks of mineralocorticoid blockade does not improve insulin sensitivity in type 2 diabetes
Finsen, S. H., Hansen, M. R., Hoffmann‐Petersen, J., Højgaard, H. F., & Mortensen, S. P. (2021) · Physiological Reports · doi:10.14814/phy2.14971 · Cited by 3
“…have demonstrated an increase in levels of HbA1c in individuals receiving the non- selective MR antagonist Spironolactone (Yamaji et al., 2010; Zhao et al., 2016), whereas no changes in HbA1c were observed with the selective MR antagonist Finerenone in Phase II studies (Agarwal et al., 2020).”
BackgroundHaq, N., Uppal, P., Abedin, T., & Lala, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093213 · Cited by 7
“MRAs can help mitigate tissue inflammation and end-organ end-organ damage by inhibiting MR overactivation [ 45, 46].”
Inflammation in Diabetic Kidney Disease: Focus on New Therapeutic Considerations
Leehey, D. J., & Zhang, X. (2023) · Medical Research Archives · doi:10.18103/mra.v11i2.3614 · Cited by 3
Ma, J., Su, Q., Wang, H., Xu, J., Yuan, C., Fan, G., Ying, J., & Bian, X. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s564942 · Cited by 2
Jin, Y., Fan, M., Zheng, X., & Zhu, S. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2392006 · Cited by 4
“Hyperkalemia was the most frequently ADR in two major clinical studies [11,33], attributable to the potas-sium-sparing effect of MRAs [34–36].”
Ob, K., Васильевич, Б. В., Викторовна, Б. Н., Викторович, Ж. В., Landar, L. N., & Владимировна, С. М. (2024) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2024-2393 · Cited by 2
Role and application prospective of non-steroidal MRA in the treatment of diabetic kidney disease
Sun, Y., & Wang, M. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04456-8 · Cited by 2
“[68].”
Research Progress in Finerenone in Cardiovascular Diseases
Sun, X., Yanghong, D., Gu, J., Wenxiu, L., & Liu, Y. (2023) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2023.0060 · Cited by 2
Zhang, R., Wang, Q., Zhou, X., Li, Q., Dong, Z., & Chen, X. (2023) · Preprints.org · doi:10.20944/preprints202308.2062.v1 · Cited by 2
Piasecki, A., Sitnik, M., Olszewski, J., Bara, M., Herjan, K., & Armański, P. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.181 · Cited by 1
Rathaur, S., Varshney, P., Vishwakarma, S., Maity, D., Khan, S. R., & Gayen, J. R. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2565142 · Cited by 1
Mechanistic Understanding of Finerenone in Hypertension Management: A Narrative Review
Prasad, M., Rashid, S. A., YASHVANTHAN, V. R., Prakash, B. M., & Priya, M. D. L. (2025) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3217 · Cited by 1
Lin, J., Fang, F., Huang, S., Wen, Z., Mai, D., Liu, J., Li, Y., Ran, J., Lan, Y., Hu, F., et al. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101250 · Cited by 1
“27 Indeed, elevated UACR is a strong predictor of both kidney injury and cardiovascular events.”
Taal, M. W. (2026) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2026.151692 · Cited by 1
Elhassan, M. M., Mahmoud, A. M., Hegazy, M. A. M., & Mowaka, S. (2026) · Journal of Nanoparticle Research · doi:10.1007/s11051-026-06577-2 · Cited by 1
Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
Chakraborty, D. S., Choudhury, S., & Lahiry, S. (2022) · Medicina Moderna - Modern Medicine · doi:10.31689/rmm.2021.29.1.25 · Cited by 2
Finerenone: pharmacological profile
Urbánek, K. (2023) · Klinická farmakologie a farmacie · doi:10.36290/far.2023.005 · Cited by 1
“typu a chronickým onemocněním ledvin studována ve dvou placebem kontrolovaných, multicentrických, randomizovaných a dvojitě zaslepených studiích fáze III klinického hodnocení nazvaných FIDELIO-DKD a FIGARO-DKD (13).”
InfluentialRenal and Heart Failure Interrelationship in Hypertension
Redón, J. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-39315-0_9 · Cited by 1
Actualización de tratamiento farmacológico de enfermedad Renal en pacientes diabéticos.
Chiluisa-Castillo, W. A., & Castro, A. S. B. (2023) · MQRInvestigar · doi:10.56048/mqr20225.7.3.2023.3494-3515 · Cited by 1
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v2 · Cited by 1
Finerenone: Do We Really Need an Additional Therapy in Type 2 Diabetes Mellitus and Kidney Disease?
Manoharan, D., Gangoo, N., & Hinchliffe, W. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0715 · Cited by 1
Aldosteronantagonisten „revisited“
Swolinsky, J. S., & Schmidt-Ott, K. M. (2022) · Die Nephrologie · doi:10.1007/s11560-022-00576-9
“Aufgrund der Kontraindikation für steroidale MRA bei schwerer Nierenfunktionseinschränkung (geschätzte GFR [eGFR] <30ml/min/1,73m2) kommen diese Substanzen bei einem Großteil der Patienten/ PatientinnenmitHerzinsuffizienzundDM2 nicht zumEinsatz: Auchbei einer eGFR von 30–60ml/min/1,73m2 ist die Verordnung dieser Medik…”
BackgroundResearch Progress in the Application of Finerenone in Patients with DKD
孟, 浩. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1291199
ACVIM, D. J. C. D. D., & Schenck, P. A. (2023) · Wiley eBooks · doi:10.1002/9781119380443.ch7
D’Errico, M. M. (2022) · The Journal of AMD · doi:10.36171/jamd22.25.4.5
Naeem, A., Zahid, N., Safir, F. N., Anwar, A., Soomro, A. K., Alyas, Z., & Shahzad, K. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2023174666
Medical use of finererone in patients with diabetes mellitus and chronic kidney disease
Severino, R. S. (2024) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2023.11.00269
Nandhitha, N. M., & Roslin, S. E. (2024) · International Conference on Advances in Electrical, Computing, Communication and Sustainable Technologies (ICAECT) · doi:10.1109/icaect60202.2024.10469292
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21510376
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21510373
Arterial hypertension in metabolic syndrome, 2024
Nussbaumerová, B., & Rosolová, H. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.018
Ob, K., Васильевич, Б. В., Викторовна, Б. Н., Landar, L. N., Serdyuk, S. V., & Владимировна, С. М. (2024) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2024-28-3-9-18
Ob, K., Викторовна, Б. Н., Васильевич, Б. В., Викторович, Ж. В., & Владимировна, С. М. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3064
Finerenone’s safety and efficacy in membranous nephropathy: an emerging perspective
Afzal, A., Fatima, A., & Razzaq, A. A. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04557-4
Top 50 cited articles on the treatment of chronic kidney disease: a bibliometric analysisPreprint
Alshahrani, A. S., Alodhaib, N. A., Alhartani, M., Gharawi, L. M., Alshedokhi, S., AlDafas, A., Alabdullah, Z., & Bassiony, M. A. A. (2025) · medRxiv · doi:10.64898/2025.12.15.25342322
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26646571
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26646577
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26646565
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26646583
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26646580
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26646559
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26646568
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26646553
Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T., & Paulissen, J. H. J. (2024) · Figshare · doi:10.6084/m9.figshare.26646574
Metadata
- Authors
- Agarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., Joseph, A., & on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators
- Affiliations
- Richard L. Roudebush VA Medical Center (US)
- German Centre for Cardiovascular Research (DE)
- University of Chicago (US)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- University of Copenhagen (DK)
- Hospital Universitario 12 De Octubre (ES)
- Bayer (Germany) (DE)
- Corresponding author
- Agarwal, Rajiv
- ORCID
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-12-06
- Volume
- 37
- Issue
- 6
- Pages
- 1014-1023
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC9130026
- OpenAlex
- W3110972804
- Cited by
- 103
- References
- 44
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 28 · 2023: 23 · 2022: 17 · 2021: 15
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, cc-by-nc-nd)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
- Funders
- Bayer AG
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- finerenone, chronic kidney disease, type 2 diabetes, mineralocorticoid receptor antagonists, diabetic nephropathy, renal failure, cardiovascular outcomes, FIDELIO-DKD, FIGARO-DKD, heart failure, renal fibrosis, quality of life
- MeSH terms
- Mineralocorticoid Receptor Antagonists, Animals, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Renal Dialysis, Humans, Naphthyridines, Quality of Life, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.